title: Clottable to immunological fibrinogen ratio in plasma from control subjects and hyperfibrinogenemic patients.
abstract: The measurement of fibrinogen (Fg) plasma levels is one of the more frequently performed tests in clinical practice, usually by clotting assay. However, for the diagnosis of dysfibrinogenemia the use of an immunological assay is necessary to compare total and clottable protein. Little information is available on the range of the ratio clottable (C) Fg/immunological (I) Fg levels in normal population. This study aimed at evaluating the CFg/IFg ratio in 70 control subjects (age range 17-74 years-group A), in 57 acute patients (age range 17-79 years-group B) and in 14 pregnant women (age range 27-41 years, pregnancy weeks 30-40-group C), as a physiologic model of hyperfibrinogenemia. CFg was assayed on citrated plasma by the Clauss clotting method and IFg was assayed by radial immunodiffusion technique. In the three groups, CFg/IFg ratios were not significantly different (respectively group A 0.98 +/- 0.17, group B 1.02 +/- 0.18 and group C 1.01 +/- 0.11), whereas both CFg (310 +/- 45 mg/dl) and IFg (326 +/- 70 mg/dl) levels were lower (p < 0.001) in control subjects than in patients (CFg 556 +/- 92 mg/dl; IFg 561 +/- 121 mg/dl) and in pregnant women (CFg 530 +/- 65 mg/dl; IFg 530 +/- 77 mg/dl). The analysis of the relationship between CFg and IFg in the three groups (group A: y = 11.53 + 1.01x, r = 0.64, p < 0.001; group B: y = 68.72 + 0.88x, r = 0.67, p < 0.0001; group C: y = 71.59 + 0.87x, r = 0.73, p < 0.01) indicates that a good correlation exists (p < 0.001) for values of fibrinogenemia ranging from 180 to over 700 mg/dl. A reference range of CFg/IFg (mean +/- 2 SD in group A) was 0.64-1.32. These data could be of practical importance for a rapid screening of dysfibrinogenemias.
authors.affiliation: Istituto di Clinica Medica Generale e Cardiologia, University of Florence, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Prisco
authors.forename: N
authors.initials: N
authors.lastname: Zarone
authors.forename: A A
authors.initials: AA
authors.lastname: Liotta
authors.forename: A P
authors.initials: AP
authors.lastname: Cellai
authors.forename: P
authors.initials: P
authors.lastname: Comeglio
authors.forename: S
authors.initials: S
authors.lastname: Fedi
authors.forename: I
authors.initials: I
authors.lastname: Francalanci
authors.forename: R
authors.initials: R
authors.lastname: Abbate
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000378:metabolism; D001780:Blood Coagulation Tests; D016022:Case-Control Studies; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000032:analysis*; D006487:Hemostasis; D006801:Humans; D005779:Immunodiffusion; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D012016:Reference Values
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005340:Fibrinogen